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Polyamide platinum anti-cancer complexes designed to target specific DNA
sequences
Abstract
Two new platinum complexes, trans-chlorodiammine[N-(2-aminoethyl)-4-[4-(Nmethylimidazole-2-carboxamido)-N-methylpyrrole-2-carboxamido]-Nmethylpyrrole-2-carboxamide]platinum(II) chloride (DJ1953-2) and trans-chlorodiammine[N(6-aminohexyl)-4-[4-(N-methylimidazole-2-carboxamido)-N-methylpyrrole-2-carboxamido]-Nmethylpyrrole-2-carboxamide]platinum(II) chloride (DJ1953-6) have been synthesized as proof-of-concept
molecules in the design of agents that can specifically target genes in DNA. Coordinate covalent binding
to DNA was demonstrated with electrospray ionization mass spectrometry. Using circular dichroism,
these complexes were found to show greater DNA binding affinity to the target sequence:
d(CATTGTCAGAC)2, than toward either d(GTCTGTCAATG)2, which contains different flanking sequences,
or d(CATTGAGAGAC)2, which contains a double base pair mismatch sequence. DJ1953-2 unwinds the
DNA helix by around 13°, but neither metal complex significantly affects the DNA melting temperature.
Unlike simple DNA minor groove binders, DJ1953-2 is able to inhibit, in vitro, RNA synthesis. The
cytotoxicity of both metal complexes in the L1210 murine leukaemia cell line was also determined, with
DJ1953-6 (34 μM) more active than DJ1953-2 (>50 μM). These results demonstrate the potential of
polyamide platinum complexes and provide the structural basis for designer agents that are able to
recognize biologically relevant sequences and prevent DNA transcription and replication.
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Polyamide Platinum Anticancer Complexes Designed to Target Specific
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Two new platinum complexes, trans-chlorodiammine[N-(2-aminoethyl)-4-[4-(N-methylimidazole-2-carboxamido)-Nmethylpyrrole-2-carboxamido]-N-methylpyrrole-2-carboxamide]platinum(II) chloride (DJ1953-2) and trans-chlorodiammine[N-(6-aminohexyl)-4-[4-(N-methylimidazole-2-carboxamido)-N-methylpyrrole-2-carboxamido]-N-methylpyrrole-2-carboxamide]platinum(II) chloride (DJ1953-6) have been synthesized as proof-of-concept molecules in the design of agents
that can specifically target genes in DNA. Coordinate covalent binding to DNA was demonstrated with electrospray
ionization mass spectrometry. Using circular dichroism, these complexes were found to show greater DNA binding
affinity to the target sequence: d(CATTGTCAGAC)2, than toward either d(GTCTGTCAATG)2, which contains different
flanking sequences, or d(CATTGAGAGAC)2, which contains a double base pair mismatch sequence. DJ1953-2
unwinds the DNA helix by around 13°, but neither metal complex significantly affects the DNA melting temperature.
Unlike simple DNA minor groove binders, DJ1953-2 is able to inhibit, in vitro, RNA synthesis. The cytotoxicity of
both metal complexes in the L1210 murine leukaemia cell line was also determined, with DJ1953-6 (34 µM) more
active than DJ1953-2 (>50 µM). These results demonstrate the potential of polyamide platinum complexes and
provide the structural basis for designer agents that are able to recognize biologically relevant sequences and
prevent DNA transcription and replication.

Introduction
Cancer continues to claim millions of lives worldwide,
with an estimated 7.1 million people dying from the disease
in 2002.1 One leading anticancer agent, cisplatin, is useful
in treating some human cancers but is limited by both its
side-affects and the ability of some cancer cells to acquire a
resistance to the drug.2-4 In the search for more efficacious
and less toxic anticancer agents, new drugs are being
developed which can specifically target cancerous cells
without affecting normal cells.
* To whom correspondence should be addressed. E-mail:
j.aldrich-wright@uws.edu.au. Phone: +61 2 4620 3218. Fax: +61 2 4620
3025.
‡ University of Western Sydney.
† University of Wollongong.
§ University of California, San Diego.
(1) The World Health Report; World Health Organization: Geneva,
Switzerland, 2003; p 19.
(2) Wong, E.; Giandomenico, C. M. Chem. ReV. 1999, 99, 2451.
(3) Hartmann, J. T.; Lipp, H. P. Expert Opin. Pharmacother. 2003, 4,
889.
(4) Baird, R. D.; Kaye, S. B. Eur. J. Cancer 2003, 39, 2450.
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One specific target of designer drugs could be telomeres,
specialized structures at the end of eukaryotic chromosomes
that modulate chromosome replication,5,6 usually comprising
a G- or C-rich repeat sequence (TTAGGG in humans).7
During cell division in normal cells, telomeres shorten in
length due to the inability of DNA polymerase to replicate
the ends of linear DNA.8,9 In contrast, many cancerous cells
show no net loss of telomere length upon cell division.10,11
Accordingly, drugs which bind to telomere sequences in
DNA or block telomerase activity could specifically target
cancer cells. Another possible drug target is the cancer
suppressor p53 protein, which regulates cell growth by either
preventing or initiating programmed cell death.12 About 50%
(5)
(6)
(7)
(8)
(9)
(10)

Blackburn, E. H.; Szostak, J. W. Annu. ReV. Biochem. 1984, 53, 163.
Blackburn, E. H. Nature 1991, 350, 569.
Zakian, V. A. Annu. ReV. Genet. 1989, 23, 579.
Watson, J. D. Nature New Biol. 1972, 239, 197.
Olovnikov, A. J. Theor. biol. 1973, 41, 181.
Counter, C. M.; Botelho, F. M.; Wang, P.; Harley, C. B.; Bacchetti,
S. J. Virol. 1994, 68, 3410.
(11) Greider, C. W.; Blackburn, E. H. Cell 1985, 43, 405.
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of human cancers show genetic mutations in the p53 gene,
preventing normal expression.13,14 Since cancer is the unchecked proliferation of cells, p53’s role is critical. Inactivation of p53 occurs by the binding of the protein coded by
the murine double minute-2 gene (MDM2).15 The gene is
overexpressed in many human cancers and effectively
inactivates p53’s protein function.16 By selectively binding
to the MDM2 gene in DNA and blocking p53-MDM2
complex formation, novel inhibitors can reactivate the p53
pathway and program cell death in cancerous cells.17
Recently, polyamides have been developed that are capable
of recognizing specific double-stranded DNA sequences.18-20
DNA sequence recognition depends on the side-by-side
amino acid pairings oriented N-to-C with respect to the 5′
f 3′ direction of the DNA duplex.21-23 The three building
blocks N-methylpyrrole (Py), N-methylimidazole (Im), and
N-methyl-3-hydroxypyrrole (Hp) form four ring-pairings (Im/
Py, Py/Im, Hp/Py, Py/Hp), which distinguish all four
Watson-Crick base pairs.24 These pairing rules therefore
mean that, theoretically, polyamides can be synthesized that
are able to recognize DNA sequences of any length.25
Coupling the sequence specificity of polyamides to a
platinum moiety should then allow the design of a range of
agents that can target telomeres or mutant p53 genes in
cancerous cells.
In this paper, we report the synthesis of two proof-ofconcept molecules, trans-chlorodiamine[N-(6-aminoethyl)4-[4-(N-methylimidazole-2-carboxamido)-N-methylpyrrole-2-carboxamido]-N-methylpyrrole-2-carboxamide]platinum(II) chloride (DJ1953-2) and trans-chlorodiamine[N-(6-aminohexyl)-4-[4-(N-methylimidazole-2-carboxamido)N-methylpyrrole-2-carboxamido]-N-methylpyrrole-2-carboxamide]platinum(II) chloride (DJ1953-6), which contain a
polyamide group capable of recognizing 5′-TGTCA-3′ DNA
sequences (Figure 1), their DNA binding, and cytotoxicity
in the L1210 murine leukaemia cell line. The results of this
research provide the foundation in the design and synthesis
of more complex agents that will be able to specifically target
mutant p53/MDM2 genes or telomeres.
(12) Vassilev, L. T. J. Med. Chem. 2005, 48, 4491.
(13) Hollstein, M.; Sidranski, D.; Vogelstein, B.; Harris, C. C. Science 1991,
253, 49.
(14) Hainaut, P.; Hollstein, M. AdV. Cancer Res. 2000, 77, 81.
(15) Oliner, J. D.; Pietenpol, J. A.; Thiagalingam, S.; Gyuris, J.; Kinzler,
K. W.; Vogelstein, B. Nature 1993, 362, 857.
(16) Harms, K.; Nozell, S.; Chen, X. Cell. Mol. Life Sci. 2004, 61, 822.
(17) Counter, C. M.; Hirte, H. W.; Bacchetti, S.; Harley, C. B. Proc. Natl.
Acad. Sci. U.S.A. 1994, 91, 2900.
(18) White, S.; Szewczyk, J. W.; Turner, J. M.; Baird, E. E.; Dervan, P.
B. Nature 1998, 391, 468.
(19) Ellervik, U.; Wang, C. C. C.; Dervan, P. B. J. Am. Chem. Soc. 2000,
122, 9354.
(20) Foister, S.; Marques, M. A.; Doss, R. M.; Dervan, P. B. Bioorg. Med.
Chem. 2003, 11, 4333.
(21) Dervan, P. B. Bioorg. Med. Chem. 2001, 9, 2215.
(22) White, S.; Turner, J. M.; Szewczyk, J. W.; Baird, E. E.; Dervan, P.
B. J. Am. Chem. Soc. 1999, 121, 260.
(23) Herman, D. M.; Turner, J. M.; Baird, E. E.; Dervan, P. B. J. Am.
Chem. Soc. 1999, 121, 1121.
(24) Nguyen, D. H.; Szewczyk, J. W.; Baird, E. E.; Dervan, P. B. Bioorg.
Med. Chem. 2001, 9, 7.
(25) Trauger, J. W.; Baird, E. E.; Dervan, P. B. J. Am. Chem. Soc. 1998,
120, 3534.

Figure 1. DNA base sequences of the three oligonucleotides studied, along
with schematic binding models. The imidazole and pyrrole rings are shown
as shaded and unshaded circles, respectively.

Experimental Section
Reagents. Di-tert-butyl dicarbonate, N-methylpyrrole-2-carboxylic acid, 1-hydroxy-1,2,3-benzotriazole (HOBt), 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDCI), platinum(IV)
oxide, DOWEX 550A OH anion-exchange resin, and transplatin
were purchased from the Aldrich Chemical Co. N-methylimidazole2-carboxylic acid was purchased from Bachem and O-(benzotriazol1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) from
Auspep. pSP64 recombinant clone (pCC1) was donated by Suzanne
Cutts, La Trobe University. pUC19 plasmid, SP6 RNA polymerase,
>90% purity 15 U µL-1, DTT, and optimized 5× transcription
buffer was purchased from Promega. Ribonucleotide Set, 100 mM
ATP, GTP, UTP, CTP solutions were purchased from Amersham
Biosciences. RNA century marker was purchased from Ambion.
Oligonucleotides were purchased from Geneworks, Melbourne,
Australia. All other reagents and solvents used were of analytical
or high purity grade.
General Methods. Reactions were monitored by thin-layer
chromatography (TLC) using 0.25 mm thick precoated UV-sensitive
silica gel plates. Compounds were visualized with short-wave
ultraviolet light at 254 nm. Flash chromatography was carried out
using Kieselgel 60 (230-400 mesh). NMR spectra were recorded
on either a 300 Varian Unityplus or 400 MHz Varian Mercury NMR
spectrometer at 25 °C using commercially available solvents
referenced to TMS or internal standards.
DNA Melting. DNA melting profiles were acquired at 260 nm
using a Cary 1E recording spectrophotometer equipped with a
Peltier controlled cell holder and a cell length of 1 cm. The
temperature gradient in all experiments was 0.5 °C min-1. The
oligonucleotides and metal complexes were combined in sodium
phosphate buffer (10 mM), containing EDTA (1 mM) and NaCl
(40 mM) adjusted to pH 7.0. The melting temperature (Tm) was
taken to be the inflection point of the hyperchromic transition.
Circular Dichroism (CD). CD measurements were recorded on
a Jasco J-810 CD spectropolarimeter at room temperature using a
cell length of 1 cm. Titrations were performed by incrementally
adding aliquots of each platinum complex to a 2600 µL solution
of 5 µM oligonucleotide. After each addition, an average CD
spectrum from 240 to 400 nm (20 accumulations) was recorded.
The concentration of each platinum complex ranged from 0 to 10
Inorganic Chemistry, Vol. 45, No. 15, 2006
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µM. Solutions were made in sodium phosphate buffer (10 mM),
containing EDTA (1 mM) and NaCl (40 mM) adjusted to pH 7.0.
DNA Unwinding. Unwinding of negatively supercoiled DNA
was carried out as reported by Loskotova and Brabec.26 The
unwinding angle of the DNA as a result of metal complex binding,
per platinum-DNA adduct, was calculated by determining the rb
value at which the complete transformation of the supercoiled to
relaxed form of the plasmid was attained. The pUC19 plasmid was
incubated with the metal complex (dissolved in H2O) for 1 h at 37
°C. The samples were precipitated by ethanol and redissolved in
Tris/acetate-EDTA buffer (0.04 M Tris/acetate and 1 mM EDTA,
pH 7.0). Aliquots of each sample were then subjected to electrophoresis on a 1% agarose gel at 25 °C, at 80 V. The gels were
stained with ethidium bromide (EtBr) and visualized with an
electronic UV transilluminator (Ultra Lum) using Gel Doc (Biorad)
and Quantity One software.
DNA Transcription Assay. The inhibition of RNA synthesis
by DJ1953-2 was assessed using a recombinant pSP64 derivative.
Seven 1.5 mL microcentrifuge tubes were setup as follows, DNA
template (2 µL, 150 ng µL-1, final concentration 46.8 µM), NTP
(0.5 µL of each, ATP, CTP, UTP, and GTP, 100 µM), 5×
transcription buffer (4 µL), BSA (0.2 µL, 0.2 µg), and DTT (2 µL,
100 mM). DJ1953-2 was titrated into the reaction tubes at 0, 10,
20, 30, 40, 60, and 80 µM concentrations and the volume made up
to 20 µL with H2O. Experiments were commenced after reacting
for 12 h (dark, 4 °C) with the addition of 15 units of SP6 RNA
polymerase. An RNA marker was prepared during the incubation
(1 µL RNA century marker and 9 µL H2O). Loading buffer was
added to all tubes and heated to 90 °C for 10 min. The samples
were loaded hot onto a 2% formaldehyde agarose gel in FA buffer
and electrophoresed at 60 V for 3 h. The gel was visualized by
staining with EtBr and analyzed using Gel Doc/Quantitiy One
software.
Electrospray Ionization Mass Spectrometry. All mass spectra
were acquired using a Micromass (Wyntheshaw, UK) Qtof 2
spectrometer with a Z-spray probe. Reactions were performed using
solutions containing 25 µM duplex DNA and either 25 or 50 µM
platinum complex in 0.1 M ammonium acetate that had been
adjusted to pH 8.5. Spectra were obtained approximately 0 and 4
h after mixing. Samples were diluted with 0.1 M ammonium acetate
(pH 8.5) so that the final concentration of oligonucleotide was 10
µM and then injected into the mass spectrometer using a Harvard
model 22 syringe pump (Natick, MA) at a flow rate of 20 µL min-1.
Negative-ion ESI-MS were acquired using a probe tip potential of
2500 V, a cone voltage of 50 V, and the source block and
desolvation temperatures set to 60 and 80 °C, respectively. The
transport and aperture were set to 2.0 and 12.0, respectively. In
most experiments, spectra were acquired over the range 5003,000 m/z. Typically 50-70 scans were summed to obtain
representative spectra. The data points were calibrated against a
standard CsI solution (750 mM) over the same m/z range.
Synthesis of DJ1953-2. N-Methyl-4-nitropyrrole-2-carboxylic
acid (1),27 methyl N-methyl-4-nitropyrrole-2-carboxylate (2),28
methyl-4-(N-methyl-4-nitropyrrole-2-carboxamido)-N-methylpyrrole-2-carboxylate (3),27 4-(N-methyl-4-nitropyrrole-2-carboxamido)N-methylpyrrole-2-carboxylic acid (3a),27 and tert-butyl-2-[4-(Nmethyl-4-nitropyrrole-2-carboxamido)-N-methylpyrrole-2-carboxamido]ethylcarbamate (5)29 were made as previously described.
(26) Loskotova, H.; Brabec, V. Eur. J. Biochem. 1999, 266, 392.
(27) Lown, J. W.; Krzystof, K. J. Org. Chem. 1985, 50, 3774.
(28) Jaramillo, D.; Liu, Q.; Aldrich-Wright, J.; Tor, Y. J. Org. Chem. 2004,
69, 8151.
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tert-Butyl-2-aminoethylcarbamate (4). A solution of di-tertbutyl dicarbonate (1.00 g, 4.58 mmol) in CH2Cl2 (12 mL) was added
over a period of 2.5 h to a solution of the 1,2-diaminoethane (2.07
g, 35.61 mmol) in CH2Cl2 (12 mL), which was cooled in an ice
bath. The mixture was stirred at room temperature for 24 h, and
the solvent removed under reduced pressure. Water (20 mL) was
added, and the mixture filtered. The filtrate was extracted with CH2Cl2, the organic layer dried (anhydrous MgSO4), and the solvent
removed to yield the product, which was dried under vacuum. The
product was isolated as a clear oil (0.64 g, 87%). 1H NMR (300
MHz, CDCl3): δ 4.93 (bs, 1H), 3.15 (q, 2H, J ) 6.0, 10.8 Hz),
2.77 (t, 2H, J ) 6.0 Hz), 1.42 (s, 9H), 1.41 (s, 2H).
tert-Butyl-2-{4-[4-(N-methylimidazole-2-carboxamido)-Nmethylpyrrole-2-carboxamido]-N-methylpyrrole-2-carboxamido}ethylcarbamate (6). To 5 (0.05 g, 0.12 mmol) in MeOH
(20 mL) was added PtO2 (0.01 g), and the solution stirred under
H2(g) (1 atm) for 26 h. The catalyst was filtered through Celite,
DMF (3 mL) added, and MeOH was removed under vacuum.
N-Methylimidazole-2-carboxylic acid 5a (0.02 g, 0.15 mmol) was
added followed by HOBt (0.03 g, 0.19 mmol), TBTU (0.06 g, 0.19
mmol), and Et3N (0.17 mL, 1.24 mmol). The solution was stirred
for 1 h, solvent removed under reduced pressure, and the residue
purified by flash chromatography (3-5% MeOH/CH2Cl2), yielding
the product (0.03 g, 52%) as a yellow solid, which was dried under
vacuum. 1H NMR (400 MHz, d6-DMSO): δ 10.47 (s, 1H), 9.93
(s, 1H), 7.98 (t, 1H, J ) 6.0 Hz), 7.39 (d, 1H, J ) 1.2 Hz), 7.28
(d, 1H, J ) 1.5 Hz), 7.18 (d, 1H, J ) 1.5 Hz), 7.14 (d, 1H, J ) 1.8
Hz), 7.03 (d, 1H, J ) 1.2 Hz), 6.86 (bs, 2H), 3.98 (s, 3H), 3.82 (s,
3H), 3.78 (s, 3H), 3.18 (m, 2H), 3.04 (m, 2H), 1.37 (s, 9H).
N-(2-Aminoethyl)-4-[4-(N-methylimidazole-2-carboxamido)N-methylpyrrole-2-carboxamido]-N-methylpyrrole-2-carboxamide (6a). Compound 6 (0.03 g, 0.06 mmol) and TFA/CH2Cl2
(1:1, 2 mL) containing water (40 µL) were stirred at room
temperature for 1.5 h. The solvent was removed under reduced
pressure, and the residue stirred with MeOH-washed DOWEX 550A
OH anion-exchange resin (0.05 g, 0.17 mmol). The solution was
decanted and evaporated, CHCl3 (5 mL) added, and the solid (0.02
g, 90%) collected and dried under vacuum. 1H NMR (400 MHz,
d6-DMSO): δ 10.49 (s, 1H), 9.96 (s, 1H), 8.13 (t, 1H, J ) 6.0
Hz), 7.71 (bs, 2H), 7.40 (d, 1H, J ) 1.5 Hz), 7.28 (d, 1H, J ) 1.5
Hz), 7.18 (d, 1H, J ) 1.5 Hz), 7.15 (d, 1H, J ) 1.8 Hz), 7.04 (d,
1H, J ) 1.2 Hz), 6.98 (d, 1H J ) 1.5 Hz), 3.98 (s, 3H), 3.83 (s,
3H), 3.81 (s, 3H), 3.5-3.2 (m, 2H), 2.92 (m, 2H).
trans-Chlorodiammine[N-(2-aminoethyl)-4-[4-(N-methylimidazole-2-carboxamido)-N-methylpyrrole-2-carboxamido]-Nmethylpyrrole-2-carboxamide]platinum(II) Chloride (DJ19532). Transplatin (0.10 g, 0.34 mmol) and 6a (0.14 g, 0.34 mmol) in
H2O (45 mL) were refluxed for 24 h until the mixture dissolved.
The solution was then cooled and filtered. The solvent was removed
under reduced pressure, and MeOH (10 mL) added. The solid was
removed, and the filtrate concentrated. CH2Cl2 was added (10 mL)
and stirred for 30 min. The resulting precipitate (0.15 g, 63%) was
collected and dried under vacuum. 1H NMR (400 MHz, d6DMSO): δ 11.52 (s, 1H), 10.09 (s, 1H), 8.17 (t, 1H, J ) 5.4 Hz),
7.53 (s, 1H), 7.44 (s, 1H), 7.29 (s, 1H), 7.19 (s, 1H), 7.17 (s, 1H),
7.14 (s, 1H), 7.04 (s, 1H), 6.97 (s, 1H), 4.01 (s, 6H), 3.91 (s, 3H),
3.82 (s, 6H), 2.93 (m, 4H); ESI-MS m/z calcd for C19H31ClN10O3Pt [M + H]+ 677.18, found 677.0
Synthesis of DJ1953-6. Methyl-4-(N-methylimidazole-2-carboxamido)-N-methylpyrrole-2-carboxylate (7). Compound 2
(29) Wade, W. S.; Mrksich, M.; Dervan, P. B. J. Am. Chem. Soc. 1992,
114, 8783.
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(0.10 g, 0.54 mmol) in MeOH (30 mL) and Pd/C (10%, 0.02 g)
were stirred under H2(g) (1 atm) for 1 h. The mixture was filtered
through Celite, DMF (3 mL) was added, and the MeOH removed
under reduced pressure. N-Methylimidazole-2-carboxylic acid 5a
(0.08 g, 0.65 mmol) was added followed by HOBt (0.11 g, 0.82
mmol), TBTU (0.26 g, 0.82 mmol), and Et3N (0.38 mL, 2.71
mmol). The solution was stirred for 1 h, the solvent removed under
reduced pressure, and the residue purified by flash chromatography
(10% MeOH/CH2Cl2), yielding the product (0.09 g, 64%) as a
cream-colored solid. 1H NMR (400 MHz, d6-DMSO): δ 10.55 (s,
1H), 7.53 (d, 1H, J ) 2.1 Hz), 7.39 (d, 1H, J ) 1.0 Hz), 7.03 (d,
1H, J ) 1.0 Hz), 7.02 (d, 1H, J ) 1.8 Hz), 3.97 (s, 3H), 3.83 (s,
3H), 3.72 (s, 3H).
4-(N-Methylimidazole-2-carboxamido)-N-methylpyrrole-2carboxylic acid (7a). To 7 (0.07 g, 0.25 mmol) in THF/MeOH
(1:1, 6 mL) was added LiOH (1 M, 6 mL), and the solution was
stirred at 60 °C for 1.5 h. The organic solvents were removed under
reduced pressure, and the solution acidified with HCl (1 M, pH 3).
The solid (0.06 g, 96%) was collected and dried under vacuum. 1H
NMR (400 MHz, d6-DMSO): δ 12.20 (bs, 1H), 10.48 (s, 1H), 7.45
(d, 1H, J ) 1.8 Hz), 7.38 (s, 1H), 7.03 (s, 1H), 6.97 (d, 1H, J )
1.8 Hz), 3.97 (s, 3H), 3.81 (s, 3H).
Methyl-4-[4-(N-methylimidazole-2-carboxamide)-N-methylpyrrole-2-carboxamide]-N-methylpyrrole-2-carboxylate (8). A
solution of 2 (0.07 g, 0.40 mmol) in MeOH (30 mL) and Pd/C
(10%, 0.02 g) was stirred under H2(g) (1 atm) for 1 h. The mixture
was filtered through Celite, DMF (3 mL) was added, and the MeOH
was removed under reduced pressure. 7a (0.07 g, 0.27 mmol) was
added followed by HOBt (0.05 g, 0.35 mmol), TBTU (0.11 g, 0.35
mmol), and Et3N (0.30 mL, 1.30 mmol). The solution was stirred
for 1 h, the solvent removed under reduced pressure, and the residue
purified by flash chromatography (2% MeOH/CH2Cl2), yielding
the product (0.09 g, 87%) as a light brown solid, which was dried
under vacuum. 1H NMR (400 MHz, d6-DMSO): δ 7.38 (d, 1H, J
) 2.1 Hz), 7.33 (d, 1H, J ) 2.1 Hz), 7.26 (d, 1H, J ) 1.0 Hz) 7.06
(d, 1H, J ) 1.0 Hz), 6.95 (d, 1H, J ) 2.1 Hz), 6.94 (d, 1H, J ) 2.4
Hz), 4.06 (s, 3H), 3.93 (s, 3H), 3.90 (s, 3H), 3.80 (s, 3H).
4-[4-(N-Methylimidazole-2-carboxamide)-N-methylpyrrole-2carboxamide]-N-methylpyrrole-2-carboxylic Acid (8a). To 8
(0.04 g, 0.12 mmol) in THF/MeOH (1:1, 2 mL) was added LiOH
(1 M, 2 mL), and the solution stirred at 60 °C for 1.5 h. The solvent
was evaporated, the solution cooled and acidified with HCl (1 M,
pH 3). The solid (0.04 g, 94%) was collected and dried under
vacuum. 1H NMR (400 MHz, d6-DMSO): δ 12.17 (bs, 1H), 10.49
(s, 1H), 9.93 (s, 1H), 7.42 (d, 1H, J ) 2.1 Hz), 7.39 (d, 1H, J )
2.1 Hz), 7.27 (d, 1H, J ) 1.0 Hz) 7.17 (d, 1H, J ) 1.0 Hz), 7.03
(d, 1H, J ) 2.1 Hz), 6.83 (d, 1H, J ) 2.4 Hz), 3.98 (s, 3H), 3.83
(s, 3H), 3.81 (s, 3H).
tert-Butyl-6-aminohexylcarbamate (9). A solution of di-tertbutyl-dicarbonate (1.00 g, 4.58 mmol) in CH2Cl2 (12 mL) was added
over a period of 2.5 h to a solution of the 1,6-diaminohexane (4.14
g, 35.61 mmol) in CH2Cl2 (12 mL), which was cooled in an ice
bath. The mixture was stirred at room temperature for 24 h, and
the solvent removed under reduced pressure. Water (20 mL) was
added, and the mixture filtered. The filtrate was extracted with CH2Cl2, the organic layer dried (anhydrous MgSO4), and the solvent
removed to yield the product, which was dried under vacuum. The
product was isolated as an oil (2.57 g, 81%). 1H NMR (300 MHz,
CDCl3): δ 4.51 (bs, 1H), 3.05 (q, 2H, J ) 6.3 Hz, J ) 12.9 Hz),
2.66 (t, 2H, J ) 6.9 Hz), 2.15 (s, 2 H), 1.40 (s, 9H), 1.29 (m, 8H).
tert-Butyl-6-{4-[4-(N-methylimidazole-2-carboxamido)-Nmethylpyrrole-2-carboxamido]-N-methylpyrrole-2-carboxamido}hexylcarbamate (10). To a mixture of 8a (0.08 g, 0.21 mmol), 9

(0.06 g, 0.27 mmol), HOBt (0.04 g, 0.31 mmol), and TBTU (0.01
g, 0.31 mmol) in DMF (5 mL) was added Et3N (0.30 mL, 1.30
mmol), and the solution was stirred for 1 h. The solvent was
removed under reduced pressure, and the residue purified by flash
chromatography (10% MeOH/CH2Cl2), to yield the product (0.09
g, 79%) as a light brown solid, which was dried under vacuum. 1H
NMR (400 MHz, d6-DMSO): δ 10.48 (s, 1H), 9.91 (s, 1H), 7.99
(t, 1H, J ) 6.0 Hz) 7.39 (d, 1H, J ) 1.2 Hz), 7.28 (d, 1H, J ) 1.5
Hz), 7.17 (d, 1H, J ) 1.5 Hz) 7.14 (d, 1H, J ) 1.8 Hz), 7.04 (d,
1H, J ) 1.2 Hz), 6.84 (d, 1H, J ) 1.5 Hz), 6.79 (bs, 1H), 3.98 (s,
3H), 3.83 (s, 3H), 3.78 (s, 3H), 3.12 (m, 2H), 1.49 (m, 2H), 1.35
(s, 17H).
N-(6-Aminohexyl)-4-[4-(N-methylimidazole-2-carboxamido)N-methylpyrrole-2-carboxamido]-N-methylpyrrole-2-carboxamide (10a). To a solution of 10 (0.07 g, 0.13 mmol) in CH2Cl2 (2
mL) was added TFA/CH2Cl2 (1:1, 2 mL) containing H2O (40 µL),
and the solution was stirred for 1.5 h. The solvent was removed
under reduced pressure, and the residue stirred with MeOH-washed
DOWEX 550A OH anion-exchange resin (0.04 g, 0.13 mmol). The
solution was decanted and evaporated, CHCl3 (5 mL) added, and
the solid (0.05 g, 90%) collected and dried under vacuum. 1H NMR
(400 MHz, d6-DMSO): δ 10.49 (s, 1H), 9.91 (s, 1H), 8.01 (t, 1H,
J ) 6.0 Hz) 7.94 (s, 1H), 7.59 (bs, 2H) 7.41 (s, 1H), 7.27 (s, 1H),
7.15 (s, 1H), 7.05 (s, 1H), 6.89 (s, 1H), 3.98 (s, 3H), 3.83 (s, 3H),
3.78 (s, 3H), 2.76 (m, 2H), 1.49 (m, 2H), 1.29 (m, 8H).
trans-Chlorodiammine[N-(6-aminohexyl)-4-[4-(N-methylimidazole-2-carboxamido)-N-methylpyrrole-2-carboxamido]-Nmethylpyrrole-2-carboxamide]platinum(II) Chloride (DJ19536). Transplatin (0.04 g, 0.13 mmol) and 10a (0.06 g, 0.13 mmol)
in H2O (20 mL) were refluxed for 24 h until the mixture dissolved.
The solution was then cooled and filtered. The solvent was removed
under reduced pressure, MeOH (10 mL) added, and the solid
removed. The filtrate was concentrated, CH2Cl2 added (10 mL) and
stirred for 30 min. The resultant solid (0.09 g, 80%) was collected
and dried under vacuum. 1H NMR (400 MHz, d6-DMSO): δ 11.42
(s, 1H), 10.05 (s, 1H), 8.03 (t, 1H, J ) 5.4 Hz), 7.57 (d, 1H, J )
1.5 Hz), 7.44 (d, 1H, J ) 1.5 Hz), 7.33 (d, 1H, J ) 1.2 Hz), 7.28
(s, 1H), 7.16 (d, 1H, J ) 1.5 Hz), 7.14 (d, 1H, J ) 1.8 Hz), 7.11
(s, 1H), 6.89 (d, 1H, J ) 1.8 Hz), 4.01 (s, 6H), 3.91 (s, 3H), 3.84
(s, 3H), 3.79 (s, 3H), 2.88 (m, 2H), 2.74 (m, 2H), 1.51 (m, 4H),
1.29 (m, 4H); ESI-MS m/z calcd for C23H39ClN10O3Pt [M + H]+
733.25, found 733.0.

Results
Metal Complex Synthesis. The synthesis of DJ1953-2
began with the nitration of the commercially available
N-methylpyrrole-2-carboxylic acid to give derivative 1. The
nitro acid was protected as its methyl ester (2), reduced by
catalytic hydrogenation, and coupled with the acid chloride
(2a), to give 3 in 82% yield (Scheme 1). Hydrolysis of the
ester and reaction of 3a with the Boc-protected diamine 4,
in the presence of EDCI as the coupling agent, afforded the
nitro intermediate 5. Final coupling with N-methylimidazole2-carboxylic acid (5a), after reduction of 5 with platinum(IV) oxide, gave the protected tripeptide 6 in a 52% yield.
The free amine 6a, isolated after removal of the Boc group
with trifluoroacetic acid, was stirred with DOWEX OH
anion-exchange resin and then reacted with transplatin to
give the metal complex in 63% yield.
In the reduction of the nitro dipyrrole (5), the more reactive
PtO2 was the catalyst of choice. In a number of reactions,
Inorganic Chemistry, Vol. 45, No. 15, 2006
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Scheme

1a

a Reagents and conditions: (a) 10% Pd/C, H
2(g), MeOH, 1 h; (b) 2a, DIEA, THF, 30 min; (c) NaOH, EtOH, 80 °C; (d) 4, EDCI/HOBt, DCM, 20 h; (e)
PtO2, H2(g), MeOH, 26 h; (f) 5a, TBTU/HOBt, Et3N, DMF, 1 h; (g) TFA/DCM, then DOWEX 550A OH anion-exchange resin; (h) H2O, transplatin, 100
°C, 24 h.

10% palladium on carbon gave poor results (incomplete
reaction, long reaction times) even at high pressures (5060 psi) and elevated temperatures (40-55 °C). The free
amine generated was also found to be extremely unstable
and was reacted without isolation. Formation of its hydrochloride was unfeasible due to the inclusion of the acidlabile Boc group.
DJ1953-6 was obtained by the successive coupling of the
amine component to the corresponding activated acid
(Scheme 2). The TBTU-mediated reactions using the additive
HOBt, in the presence of Et3N, allowed for the rapid
construction of the growing polyamide in high yields. Thus,
the nitro ester (2) was reduced with Pd/C in MeOH and
coupled to the in situ activated acid (5a) to give the amide
(7). Repeated couplings afforded compounds 8 and 10 in
87% and 79% yields, respectively. Final deprotection and
attachment to transplatin gave the metal complex in 80%
yield. The final compounds and intermediates were characterized by NMR and mass spectrometry. In all cases, NMR
chemical shifts were comparable to published values.27,29,30
(30) Krapcho, A. P.; Mareach, M. J.; Lunn, J. Synth. Commun. 1993, 23,
2443.
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DNA Melting. DNA melting studies were used to assess
the impact of the platinum complexes on the thermal stability
of DNA. Thermal denaturation experiments were conducted
with both metal complexes and three oligonucleotides in 40
mM NaCl, which is comparable to the salt concentrations
used for other platinum metal complexes.31-34 Duplex 1
d(CATTGTCAGAC)2 contains a central five-base-pair sequence which is the target site for DJ1953-2 and DJ19536. Duplex 2 d(GTCTGTCAATG)2 contains the same central
binding site as duplex 1 but surrounded by different flanking
sequences, while duplex 3 d(CATGAGAGAC)2 contains a
double-base-pair mismatch sequence. In the experiments, the
amount of oligonucleotide was kept constant while the metal
complex concentration ratio was varied with respect to the
DNA. The results demonstrated there was no significant
(31) Kasparkova, J.; Novakova, O.; Vrana, O.; Farrell, N.; Brabec, V.
Biochemistry 1999, 38, 10997.
(32) Gonzalez, V. M.; Amo-Ochoa, P.; Perez, J. M.; Fuertes, M. A.;
Masaguer, J. R.; Navarro-Ranninger, C.; Alonso, C. J. Inorg. Biochem.
1996, 63, 57.
(33) Brabec, V.; Kasparkova, J.; Vrana, O.; Novakova, O.; Cox, J. W.;
Farrell, N. Biochemistry 1999, 38, 6781.
(34) Kloster, M.; Kostrhunova, H.; Zaludova, R.; Malina, J.; Kasparkova,
J.; Brabec, V.; Farrell, N. Biochemistry 2004, 43, 7776.
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Scheme 2 a

a Reagents and conditions: (a) 10% Pd/C, H
2(g), MeOH, 1 h; (b) 5a, TBTU/HOBt, Et3N, DMF, 1 h; (c) LiOH, THF/MeOH, 60 °C, 1.5 h; (d) 2, 10% Pd/C,
H2(g), MeOH, 1 h; (e) TBTU/HOBt, Et3N, DMF, 1 h; (f) 9, TBTU/HOBt, Et3N, DMF, 1 h; (g) TFA/DCM, then DOWEX 550A OH anion-exchange resin;
(h) H2O, transplatin, 100 °C, 24 h.

Figure 2. Unwinding of supercoiled pUC19 plasmid DNA by DJ1953-2. Lanes: 0 control rb ) 0; 1 rb ) 0.008; 2 rb ) 0. 0.016; 3 rb ) 0.025; 4 rb )
0.033; 5 rb ) 0.041; 6 rb ) 0.049; 7 rb ) 0.057; 8 rb ) 0.066; 9 rb ) 0.074. The coalescence point (rb) denotes the bound metal complex-to-nucleotide ratio.

change in the Tm of any of the three oligonucleotides with
either metal complex.
DNA Unwinding. Unwinding of the DNA double helix
is signaled by a decrease in the supercoiled density of closed
circular DNA, and the degree of unwinding is determined
by the rate of the DNA’s migration through an agarose gel.35
Figure 2 shows the results of gel electrophoresis on supercoiled pUC19 DNA after reaction with DJ1953-2 at drugto-nucleotide ratios of between 0.008 and 0.074. A general
trend can be seen where migration is impeded with increasing
drug concentration, consistent with an increased unwinding
of DNA helix to the relaxed form. At the drug-to-nucleotide
ratio of 0.074, the DNA is at maximum relaxation and
corresponds to a 13° unwinding of the helix.

DNA Transcription Assay. The ability of the platinum
complexes to block RNA transcription was examined using
SP6 RNA polymerase and the recombinant pSP64 derivative
in transcription assays. Figure 3 shows the increasing
inhibition of the 335 base full length RNA transcript with
increasing DJ1953-2 concentration. Complete inhibition of
RNA synthesis is observed in lane 8 at a metal complex
concentration of 80 µM, and 50% inhibition of synthesis is
observed at a concentration of 46.5 µM. Importantly, the
parent compound, distamycin, is unable to block the elongation of growing RNA chains by DNA-dependent RNA
polymerases.36
(35) Keck, M. V.; Lippard, S. J. J. Am. Chem. Soc. 1992, 114, 3386.
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Figure 3. Inhibition of RNA synthesis on the recombinant pSP64
derivative modified by DJ1953-2. Lanes: 1 100-500 base RNA marker;
2 0; 3 10; 4 20; 5 30; 6 40; 7 60; 8 80 µM of DJ1953-2. The inhibition of
the full-length transcript (FLT) can be seen at 335 bases (lane 8).

ESI-MS DNA Binding. The reactivity of the platinum
complexes toward DNA was examined through ESI-MS
experiments. DNA binding profiles were measured on the
reaction of both platinum complexes with DNA containing
their target sequence. Spectra were obtained immediately
after and 4 h after the addition of metal complex. At 0 h, no
ions demonstrating oligonucleotide binding were seen. After
4 h, however, the formation of platinum-DNA adducts was
observed through the molecular ions 1938.2 and 1947.6 m/z
for DJ1953-2 and DJ1953-6, respectively, corresponding to
one monofunctional coordinate covalent adduct (complex +
one oligonucleotide strand - chloride). This result demonstrates that the metal complexes form coordinate covalent
adducts with DNA.
Circular Dichroism. CD spectropolarimetry was used to
determine the equilibrium constant and binding strength of
the platinum complexes. CD titrations were carried out by
incremental addition of DJ1953-2 and DJ1953-6 into a fixed
concentration of DNA, resulting in changes to the DNA
spectra. Preferential binding was also quantified by varying
the sequence of the oligonucleotides (target, mismatch, and
flanking bases). CD and ICD spectra obtained for DJ1953-2
are shown in Figure 4.
In the oligonucleotides studied, the characteristic positive
and negative bands for B-DNA are observed at 280 and 245
nm, respectively. Compounds DJ1953-2 and DJ1953-6 bind
to the oligonucleotides, as shown by the appearance of DNAinduced ligand CD bands at about 300-360 nm. The positive
induction at ∼320 nm is due to the UV absorption π f π*
transition of the polyamide binding in the minor groove of
the platinum-DNA complex.37-39 These DNA-induced
ligand CD bands directly correlate the interactions of the
metal complex with DNA, as the platinum complexes
themselves do not exhibit any CD spectra. Titration of each
(36) Zimmer, C. Prog. Nucl. Acids Res. Mol. Biol. 1975, 15, 285.
(37) Lee, M.; Rhodes, A. L.; Wyatt, M. D.; Forrow, S.; Hartley, J. A.
Biochemistry 1993, 32, 4237.
(38) Lacy, E. R.; Cox, K. K.; Wilson, W. D.; Lee, M. Nucl. Acids Res.
2002, 30, 1834.
(39) Lyng, R.; Rodger, A.; Norden, B. Biopolymers 1992, 32, 1201.
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platinum complex with duplex 1 (target site) produced an
intense positive band at 321 nm. Titration with duplex 2
(flanking sequence change) gave a less pronounced positive
band; however, addition of either metal complex to duplex
3 (mismatch site) produced weaker induction bands at 321
nm. The presence of the negative and positive bands of DNA
at ∼245 and 280 nm, respectively, suggests that the
conformation of DNA in the platinum-DNA complexes
remained in the B-form. The result correlates well with
crystallography and NMR evidence, which shows DNA
remains in the B-form when bound by distamycin and
netropsin.40,41
Titration curves at 320 nm extracted from the CD spectra
were then used to determine the equilibrium binding
constants (K). Determination of K was obtained directly from
the experimental data using a nonlinear least-squares fit of
a simple equilibrium model, using eq 1:42

{

BT
 1 1
)
+ LT + (
R 2 K
n

x(

)

}

BT 2 4BTLT
1
+ LT +
K
n
n

(1)

where  is the extinction coefficient in mol-1 dm3 cm-1, LT
is the total number of ligands [LF (free ligand) + LB (bound
ligand)], BT is the total number of bases, n is the number of
bases per binding site, and R is a function of wavelength.
The K values derived by this method are presented in Table
1. Apparent binding affinities of both DJ1953-2 and DJ19536, in general, follow the order: target site > flanking
sequence change > mismatch site. The only exception is
DJ1953-6 to its mismatch sequence, where the level of
binding is similar to that for the target sequence.
Cytotoxicity. The influence of polymethylene chain length
on cytotoxicity was examined against L1210 murine leukemia cells. DJ1953-6 was more active against the cell line
with an IC50 of 34 µM than DJ1953-2 (>50 µM) and is
much more active than distamycin (133 µM)43 but less than
cisplatin (0.5 µM).
Discussion
Attachment of a sequence-specific polyamide to a monofunctional platinum moiety produces a complex with synergistic effects. Experiments measuring the thermal stability
of DNA upon binding by either metal complex (DJ1953-2
or DJ1953-6) demonstrated that the complexes have no net
effect on helix stability, with no significant increase or
decrease in melting temperature. The measured differences
in melting temperature between the target site binding by
the metal complex and that of the mismatch site were
compared. These results are in contrast to the parent
compounds distamycin and netropsin which are known to
stabilize double-stranded DNA and increase its melting
(40) Patel, D. J. Proc. Natl. Acad. Sci. U.S.A. 1982, 79, 6424.
(41) Chen, X.; Ramakrishnan, B.; Rao, S. T.; Sundarlingam, M. Nat. Struct.
Biol. 1994, 1, 169.
(42) Stootman, F. H.; Fisher, D. M.; Aldrich-Wright, J. submitted for
publication.
(43) Baraldi, P. G.; Nunez, M.; Tabrizi, M. A.; De Clercq, E.; Balzarini,
J.; Bermejo, J.; Estevez, F.; Romagnoli, R. J. Med. Chem. 2004, 47,
2877.
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Figure 4. Circular dichroism and induced circular dichroism spectra at different binding ratios of DJ1953-2, with the three oligonucleotides; (top) duplex
1 d(CATTGTCAGAC)2-the target site; (middle) duplex 2 d(GTCTGTCAATG)2-flanking sequence change and (bottom) duplex 3 d(CATTGAGAGAC)2mismatch site. The data were normalized by subtracting the unbound oligonucleotide spectrum.
Table 1. Equilibrium Binding Constants, K, Determined by the Least Squares Methoda
K (M-1)
complex

d(CATTGTCAGAC)2

d(GTCTGTCAATG)2

d(CATTGAGAGAC)2

DJ1953-2
DJ1953-6

1.2 ((0.1) ×
2.4 ((0.1) × 106

5.6 ((0.2) ×
4.4 ((0.2) × 105

3.0 ((0.1) × 105
1.3 ((0.1) × 106

106

105

a K values represent initial DNA recognition and preassociation of the metal complexes before coordinate covalent bond formation and were determined
immediately after the addition of each metal complex to the oligonucleotides.

temperature.44-46 One explanation may be due to the size of
the complex. Previously it has been shown that at least four
heterocyclic rings are required to increase the melting
temperature of DNA.47 Another explanation may be that,
(44) Luck, G.; Zimmer, C.; Reiner, K. E.; Arcamone, F. Nucl. Acids Res.
1977, 4, 2655.
(45) Zimmer, C.; Luck, G.; Thrum, H.; Pitra, C. Eur. J. Biochem. 1972,
26, 81.
(46) Dyatkina, N.; Roberts, C. D.; Keicher, J. D.; Dai, Y.; Nadherny, J.
P.; Zhang, W.; Schmitz, U.; Kongpachith, A.; Fung, K.; Novikov, A.
A.; Lou, L.; Velligan, M.; Khorlin, A. A.; Chen, M. S. J. Med. Chem.
2002, 45, 805.

while the polyamide arm does stabilize the double helix, this
effect may be negated upon binding by the platinum moiety,
which may act to destabilize the helix. Some multinuclear
platinum complexes, which form coordinate covalent bonds
with DNA, have been shown under some conditions to
decrease the melting temperature of DNA.34
Previously it has been shown that small molecules, such
as the clinical agent cisplatin,48 when bound to DNA result
(47) Thomas, M.; Varshney, U.; Bhattacharya, S. Eur. J. Org. Chem. 2002,
3604.
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Figure 5. Binding of DJ1953-2 to its target and double mismatch sequence. Titration curves were obtained at 320 nm.

in an unwinding of the helix by up to 13°. To some extent
the ability of a complex to unwind DNA is correlated to its
cytotoxicity; transplatin, the trans isomer of cisplatin only
unwinds DNA by 9° and is not cytotoxic.49 To assess the
platinum complexes’ functionality of binding, DNA unwinding experiments were conducted with DJ1953-2, which was
found to unwind DNA by 13°. The parent compounds,
distamycin and netropsin, which only groove bind, do not
unwind supercoiled DNA by a significant amount.26 In
addition, the monofunctional platinum complexes trans-[Pt(NH3)2(N8-Etd)Cl]2+, (Etd ) ethidium), [Pt(NH3)3Cl]+, and
[Pt(dien)Cl]+ have also been shown to unwind DNA by only
8° and 6°, respectively.50 The results of this experiment
therefore indicate that the polyamide component of DJ1953-2
may act cooperatively with the platinum moiety to unwind
the DNA helix. It is also possible that the complex is binding
as a quasi-dinuclear platinum complex. Two DJ1953-2
molecules may bind at the same time, with the polyamide
groups of each metal complex forming an antiparallel dimer
in the DNA minor groove. The formation of dimers is well
established with polyamides;21 therefore, it is likely that two
metal complex molecules are acting together, and the two
monofunctional platinum groups produce a DNA binding
effect (like DNA unwinding) similar to a dinuclear platinum
complex. Many of the multinuclear complexes reported by
Farrell and co-workers, such as BBR3005, BBR3571, and
BBR3464, unwind DNA by 14°, 12°, and 14°, respectively,51,52 consistent with the unwinding caused by DJ19532.
Polyamides designed to target adjacent binding sites of
transcription factors involved in HIV type 1 RNA synthesis
specifically inhibit transcription in vitro.53 The transcription
factors bind to DNA in the minor groove and are likely to
be inhibited by the minor-groove-binding polyamides.54
Notably, one of the polyamide compounds of Dervan and
co-workers, which bound its target sequence, was unable to
inhibit transcription.53 The result suggested that transcription
of DNA can occur with a polyamide bound in the minor
groove and that polyamides are only inhibitory to transcription when the compound interferes with the DNA binding
activity of a required transcription factor. From transcription
assays, it was observed that DJ1953-2 can inhibit DNA
transcription, again an unusual result given that many
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monofunctional platinum complexes and native polyamides
are unable to terminate RNA synthesis;55 the clinically
ineffective compounds, [PtCl(dien)]+ and [PtCl(NH3)3]+, do
not inhibit replication and transcription. These results are
also consistent with a cooperative effect between the polyamide arm and the platinum moiety and/or a cooperative
effect between two DJ1953-2 complexes, acting as a quasidinuclear complex. Previously it has been shown that the
multinuclear platinum complexes BBR3499 and BBR3464
are very efficient at preventing DNA/RNA transcription.31,56
The assessment of DNA conformational changes by CD
demonstrated that DJ1953-2 and DJ1953-6 preferentially
bind to selective sequences of DNA. DJ1953-2 shows only
a ∼2.1-fold greater affinity for the target site [K ) (1.2 (
0.1) × 106 M-1] relative to the flanking sequence change
site [K ) (5.6 ( 0.2) × 105 M-1]. The complex, however,
exhibits a 4-fold preference for its target site versus the
mismatch site [K ) (3.0 ( 0.1) × 105 M-1].
The difference in DNA affinity correlates well with the
recognition of the side-by-side amino acid pairings. An Im/
Py pair is specific for G.C (hydrogen bond between N3 of
the imidazole ring and N2 of guanine), whereas a Py/Im pair
targets a C.G base pair.29,57 A Py/Py pair is partially
degenerate and can bind A.T or T.A base pairs.58 As
illustrated in Figure 5, the negative Py/Im pairing of the
complex in the mismatch site results in a loss of DNA
affinity. The imidazole on the cytosine side of the base pair
(48) Bellon, S. F.; Coleman, J. H.; Lippard, S. J. Biochemistry 1991, 30,
8026.
(49) Sundquist, W. I.; Lippard, S. J. Coord. Chem. ReV. 1990, 100, 293.
(50) Keck, M. V.; Lippard, S. J. J. Am. Chem. Soc. 1992, 114, 3386.
(51) McGregor, T. D.; Hegmans, A.; Kasparkova, J.; Neplechova, K.;
Novakova, O.; Penazova, H.; Vrana, O.; Brabec, V.; Farrell, N. J.
Biol. Inorg. Chem. 2002, 7, 397.
(52) Cox, J. W.; Berners-Price, S.; Davies, M. S.; Qu, Y.; Farrell, N. J.
Am. Chem. Soc. 2001, 123, 1316.
(53) Dickinson, L. A.; Gulizia, R. J.; Trauger, J. W.; Baird, E. E.; Mosier,
D. E.; Gottesfeld, J. M.; Dervan, P. B. Proc. Natl. Acad. Sci. U.S.A.
1998, 95, 12890.
(54) Jones, K. A.; Peterlin, B. M. Annu. ReV. Biochem. 1994, 63, 717.
(55) Leng, M.; Brabec, V. IARC Sci. Publ. 1994, 125, 339.
(56) Kasparkova, J.; Vrana, O.; Farrell, N.; Brabec, V. J. Inorg. Biochem.
2004, 98, 1560.
(57) Wade, W. S.; Mrksich, M.; Dervan, P. B. Biochemistry 1993, 32,
11385.
(58) Pelton, J. G.; Wemmer, D. E. Proc. Natl. Acad. Sci. U.S.A. 1989, 86,
5723.
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is unable to form a hydrogen bond with guanine’s exocyclic
amine, which points into the minor groove.51,52
DJ1953-6 binds its target sequence with a ∼5.5-fold
greater affinity [K ) (2.4 ( 0.1) × 106 M-1] than its flanking
sequence change site [K ) (4.4 ( 0.2) × 105 M-1]. Only a
1.8-fold decrease in ligand binding is observed toward the
mismatch site [K ) (1.3 ( 0.1) × 106 M-1]. The complex
does not strongly discriminate between its target and
mismatch site. Although an increase in its binding affinity
is observed, it also reduces its binding selectivity for the
match site relative to a mismatch site. Interestingly, DJ1953-6
shows a higher binding affinity compared to DJ1953-2,
particularly with the mismatched sequence. As the only
difference between the two metal complexes is the linker
length, this result indicates that the linker affects binding
affinity but probably not sequence selectivity.
The CD spectral characteristics of DJ1953-2 and DJ1953-6
are also comparable to those observed by the isomers of
cisplatin tethered to distamycin [Pt-DIST(R) and Pt-DIST(S)]. Covalent binding to ct-DNA by both of these chiral
complexes also resulted in the appearance of a CD band
centered at ∼322 nm, which was indicative of both coordination and noncovalent binding.26 The presence of an
isoelliptic point at 289 nm reflected only one distamycin
moiety binding per DNA adduct which gave rise to the
induced CD band at ∼322 nm.59 Changes induced on ctDNA, such as the loss of intensity in the positive band at
around 280 nm and a decrease in the negative band at 245
nm, were distinctly different from those observed by untargeted cisplatin60 or distamycin.61,62 Although DJ1953-2 and
DJ1953-6 are unable to induce irreversible DNA conformational changes (multinuclear complexes are able to induce
B-to-A and B-to-Z DNA transitions), they do show the
isoelliptic point at around 289 nm and display the same
modified CD bands at 245 and 280 nm.
Despite the ability of DJ1953-2 and DJ1953-6 to unwind
DNA and prevent transcription, these complexes do not show
equivalent anticancer activity with IC50 values of >50 and
(59) Kostrhunova, H.; Brabec, V. Biochemistry 2000, 39, 12639.
(60) Brabec, V.; Kleinwachter, V.; Butour, J.-L.; Johnson, N. P. Biophys.
Chem. 1990, 35, 129.
(61) Zimmer, C.; Wahnert, U. Prog. Biophys. Mol. Biol. 1986, 47, 31.
(62) Zimmer, C.; Luck, G. AdV. DNA Seq. Agents 1992, 1, 51.

34 µM (48 h assay), respectively. These results show that at
least DJ1953-6 is more cytotoxic than distamycin (IC50, 133
µM; 48 h assay),43 indicating a significant effect by the
platinum moiety. The minimal cytotoxic profiles observed
may be attributed to two factors: reduced drug uptake and
limited cellular accumulation or coordination of the complex
in the minor groove. The polyamide segment binds in the
minor groove of DNA, whereas the platinum complex forms
adducts primarily in the DNA major groove. For these metal
complexes, the binding of the polyamide arm may dominate
and prevent platinum adduct formation. This hypothesis is
supported by the cytotoxicity profile of the metal complexes,
where the short polymethylene chain of DJ1953-2 (twocarbon) results in little cytotoxicity. By tethering the platinum
moiety to a longer chain, as in DJ1953-6, an improvement
in biological activity occurs. If correct, the cytotoxicity of
these platinum complexes may be altered by changing the
chain length.
Conclusions
Two proof-of-concept compounds have been synthesized
that combine a platinum moiety, capable of coordinate
covalent bond formation with DNA, to a polyamide capable
of recognizing specific DNA sequences. These metal complexes show greater binding affinity for the target sequence
compared to the mismatch sequence. Both complexes can
form coordinate covalent bonds with DNA but appear to form
dimers in the DNA minor groove, acting as quasi-multinuclear platinum complexes.
While the cytotoxicity of either metal complex was not
better than cisplatin, they are more active than the parent,
naturally occurring distamycin polyamide, and provide the
structural basis for a new series of extended polyamides with
either mono- or dinuclear platinum complexes that can
directly target specific double-stranded DNA sequences.
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